Astech Projects Comes of Age at 18 Years Old
News Jul 10, 2013
Astech was started with the founders’ vision to be “recognised as one of the world’s best” in the design and supply of custom robotics and automation for use in advanced manufacturing industries including pharmaceutical, medical device, consumer healthcare, petro-chemical and chemical. This has largely been achieved by providing the very best automation solutions tailored to customer’s unique and individual requirements.
Having gone from strength to strength with an increasing sized workforce, two relocations to larger premises and a Queen’s Award for Enterprise: Innovation, Astech Director, Anthony Moran commented “This is a significant milestone for us and we hope it reinforces our reputation for quality and longevity. We have ambitious plans to broaden our product portfolio and to keep offering valuable solutions to our customers”. He continued: "We are committed to being ‘best in class’ and if we continue to improve we can only become even more successful. In addition to thanking our dedicated Astech team for all their hard work and commitment over the last 18 years we would like to thank our many clients that have entrusted Astech to provide them with innovative and intelligent design solutions”
To celebrate their anniversary Astech are currently offering a free consultation and proposal of their novel turnkey approach to automation which can consist of four key steps: (1) consultation & proposal, (2) concept design study, (3) proof of concept(s) and (4) detailed design, manufacture and testing. Simply complete the online form and one of Astech’s specialist Business Development Mangers will contact you.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE